As we hinted last week, Wireless sensor and neuropathology start-up NeuroVigil has inked a deal with Swiss pharamceutical company Roche. NeuroVigil will provide Roche with its iBrain wireless sensors to help the company collect and analyze data during its clinical trials. NeuroVigil technology will be used to help the company’s development of various drugs for CNS disorders. The iBrain devices are portable and noninvasive peel-and-stick wireless sensors that monitor neural activity during outpatient clinical trials.
NeuroVigil will analyze each patient’s data using its proprietary algorithms and brain-derived biomarker libraries. These analytics aim to help “Roche to detect subtle individual changes in brain activity at very low drug dosages, often before the onset of cognitive symptoms and adverse effects,” according to the companies’ press release.
“NeuroVigil is delighted to join forces with Roche, the world`s largest diagnostics company, and advance on a path of innovation and discovery, likely to accelerate the pace at which we can make early and significant contributions to the lives of many patients suffering from, or about to develop, a major neuropathological condition,” Dr. Philip Low, Founder, Chairman and CEO of NeuroVigil stated in the press release.
Low actually hinted at a deal with a big pharmaceutical company during his talk at TEDMED last week. NeuroVigil uses an adhesive, wireless sensor or a head strap both of which monitor a single channel of EEG, brainwave activity and analyzes the data using an algorithm called SPEARS. Low demonstrated the sensor wirelessly transmits a patient’s EEG to a mobile phone on-stage at the event. By wearing the sensor at night and monitoring the EEG during sleep, Low believes clinicians can use the information to diagnose early on-set of neuropathologies like Alzheimer’s.
Read the company’s press release here.